Fenster schließen  |  Fenster drucken

[posting]36976428[/posting]News:

Schön langsam wird es spannend, in der zweiten Jahreshälfte, d.h. nach meiner Berechung ab 1.7.2009:laugh: kommen die Ergebnisse:

BioMS Medical's pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
Tuesday April 21, 2009, 12:05 pm EDT
Buzz up! Print
Toronto Stock Exchange Symbol: MS
EDMONTON, April 21 /CNW/ - BioMS Medical Corp. (TSX: MS - News), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the final:eek: scheduled review by the DSMB prior to the completion of MAESTRO-01. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial. Results from MAESTRO-01 are expected in the second half of this year.


About MAESTRO-01
----------------
MAESTRO-01 is a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with secondary progressive MS. The study is being conducted at 47 sites across Canada and nine countries in Europe and includes 611 patients being administered either dirucotide or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease, as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 70% of all MS patients are HLA-DR2 and/or HLA-DR4 positive). Time to disease progression in patients with other HLA-DR types will be assessed separately as an exploratory arm of the same study.


About BioMS Medical Corp.
-------------------------
BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com
 
aus der Diskussion: Bioms im Entscheidungsjahr auf dem Weg in die "Zweistelligkeit"?
Autor (Datum des Eintrages): Magnetfeldfredy  (21.04.09 18:50:53)
Beitrag: 63 von 179 (ID:37011816)
Alle Angaben ohne Gewähr © wallstreetONLINE